AbbVie Reports long-term follow-up Data for Abemaciclib in Ovarian cancer

AbbVie today announced long-term follow-up results for abemaciclib in patients with ovarian cancer. The study demonstrated that abemaciclib improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of ovarian cancer and support the continued development of abemaciclib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.